Interactive neural network-assisted screening: An economic assessment

Acta Cytologica

Volumn 42, Issue 1, 1998, Pages 246-252

  Radensky, Paul W ^a   Mango, Laurie J ^b  

^a McDermott   (United States)

^b BD Technologies   (United States)

Author keywords

Automation; Cervical smears; Cost effectiveness; Mass screening; PAPNET

Indexed keywords

ARTIFICIAL NEURAL NETWORK; CANCER CYTODIAGNOSIS; CANCER SCREENING; COMPUTER ASSISTED DIAGNOSIS; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HEALTH CARE COST; HUMAN; PAPANICOLAOU TEST; PRIORITY JOURNAL; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CYTOLOGY;

INNA;

EID: 0031886459     PISSN: 00015547     EISSN: 19382650     Source Type: Journal    
DOI: 10.1159/000331553     Document Type: Conference Paper

References (14)

1. Baker MS, Kessler LG, Smucker RC: Analysis of the continuous Medicare history sample file: The cost of treating cancer. In Cancer Care and Costs: Proceedings of a meeting of the American Cancer Society, San Diego, California, May 1987. Edited by Scheffler RM, Andrews NC. Washington, DC, Health Administration Press, 1989, pp 127-138
2. Consumer Price Index: All Urban Consumers: US City Average. Washington, DC, Bureau of Labor Statistics, 1997
3. Eddy DM: Screening for cervical cancer. Ann Intern Med 1990;113:214-226
4. Fahey MT, Irwig L, Macaskill P: Meta-analysis of Pap test accuracy. Am J Epidemiol 1995;141:680-689
5. Gold MR, Seigel JE, Russell LB, Weinstein MC (editors): Cost Effectiveness in Health and Medicine. New York, Oxford University Press, 1996
6. Jones BA, Novis DA: Cervical biopsy-cytology correlation: A College of American Pathologists Q-Probes study of 22439 correlations in 348 laboratories. Arch Pathol Lab Med 1996;120:523-531
7. Laupacis A, Feeny D, Detsky AS, Tugwell PX: How attractive does a new technology have to be to warrant adoption and utilization?: Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992;146:473-481
8. Mango LJ, Radensky PW: Interactive neural network-assisted screening: A clinical assessment. Acta Cytol 1998;42:227-232
9. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, Barbash G, White H, Simoons ML, Nelson CL, Clap-Channing N, Knight JD, Harrell FE, Simes J, Topol EJ: Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332:1418-1424
10. Medicare 1994 Clinical Diagnostic Fee Schedule Limits (National 60% Limits). Baltimore, Health Care Financing Administration, 1994
11. Medicare Program: Revisions to payment policies and five-year review of and adjustments to the relative value units under the Physician Fee Schedule for calendar year 1997. Fed Register November 22, 1996, pp 59490-59724
12. Muller C, Mandelblatt J, Schechter CB, Power EJ, Duffy BM, Wagner JL: Costs and Effectiveness of Cervical Cancer Screening in Elderly Women. Washington, DC, US Government Printing Office, 1990
13. Schechter CB: Cost-effectiveness of rescreening conventionally prepared cervical smears by PAPNET testing. Acta Cytol 1996;40:1272-1282
14. Soost H, Lange H, Lehmacher W, Ruffing-Kullmann B: The validation of cervical cytology. Sensitivity, specificity and predictive values. Acta Cytol 1991;35:8-14